COMPANY

BlueRock Therapeutics

Keywords: iPSC Primary Photoreceptor Disease Retinitis Pigmentosa Usher Syndrome Inherited Retinal Disease Rod-Cone Dystrophy Rod-Cone Disease Retinal Degeneration Cone-Rod Disease Cone-Rod Dystrophy Parkinsons Disease Advanced Parkinson's Disease Parkinson's Disease Parkinson Disease bemdaneprocel MSK-DA01 MSK-DA01 Cell Delivery Device

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

Jun 17, 2025 Trial start Phase 3: A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease source ↗
Mar 10, 2025 Trial start Phase 1/Phase 2: A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) source ↗
May 16, 2023 Trial start —: Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01 source ↗
Jul 29, 2022 Trial start —: Noninterventional Study Evaluating Parkinson's Disease Diary Use source ↗
May 3, 2021 Trial start 1: Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease source ↗

Upcoming milestones

2027-03 (ESTIMATED) · Phase 3 · A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease · NCT06944522
2027-05 (ESTIMATED) · · Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01 · NCT05897957
2029-10 (ESTIMATED) · Phase 1/Phase 2 · A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) · NCT06789445

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06789445	A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)	Phase 1/Phase 2	Recruiting	Mar 10, 2025	2029-10 (estimated)
NCT06944522	A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease	Phase 3	Recruiting	Jun 17, 2025	2027-03 (estimated)
NCT04802733	Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease	1	Completed	May 3, 2021	May 18, 2023 (actual)
NCT05363046	Noninterventional Study Evaluating Parkinson's Disease Diary Use	Not listed	Active, not recruiting	Jul 29, 2022	2025-10 (estimated)
NCT05897957	Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01	Not listed	Enrolling by invitation	May 16, 2023	2027-05 (estimated)